-+ 0.00%
-+ 0.00%
-+ 0.00%

Tiziana Life Sciences CEO Ivor Elrifi Buys 163,400 Shares In Open Market, Increases Total Holdings To 357,848 Shares

Benzinga·12/15/2025 20:09:15
Listen to the news

Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 163,400 shares of Tiziana common stock in the open market. This brings his current purchased shares total to 357,848.